JP2024531217A5 - - Google Patents
Info
- Publication number
- JP2024531217A5 JP2024531217A5 JP2024508545A JP2024508545A JP2024531217A5 JP 2024531217 A5 JP2024531217 A5 JP 2024531217A5 JP 2024508545 A JP2024508545 A JP 2024508545A JP 2024508545 A JP2024508545 A JP 2024508545A JP 2024531217 A5 JP2024531217 A5 JP 2024531217A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- omni
- acid substitution
- acid substitutions
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163232571P | 2021-08-12 | 2021-08-12 | |
| US63/232,571 | 2021-08-12 | ||
| US202263332214P | 2022-04-18 | 2022-04-18 | |
| US63/332,214 | 2022-04-18 | ||
| US202263333037P | 2022-04-20 | 2022-04-20 | |
| US63/333,037 | 2022-04-20 | ||
| PCT/US2022/074930 WO2023019263A1 (en) | 2021-08-12 | 2022-08-12 | Engineered high fidelity omni-50 nuclease variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531217A JP2024531217A (ja) | 2024-08-29 |
| JP2024531217A5 true JP2024531217A5 (https=) | 2025-08-20 |
Family
ID=85201002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024508545A Pending JP2024531217A (ja) | 2021-08-12 | 2022-08-12 | 遺伝子改変高忠実度ｏｍｎｉ－５０ヌクレアーゼバリアント |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250283115A1 (https=) |
| EP (1) | EP4384609A4 (https=) |
| JP (1) | JP2024531217A (https=) |
| KR (1) | KR20240043792A (https=) |
| AU (1) | AU2022326575A1 (https=) |
| CA (1) | CA3228366A1 (https=) |
| IL (1) | IL310730A (https=) |
| WO (1) | WO2023019263A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024506608A (ja) | 2021-02-08 | 2024-02-14 | エメンドバイオ・インコーポレイテッド | Ｏｍｎｉ－１０３ ｃｒｉｓｐｒヌクレアーゼ |
| US12091688B2 (en) | 2021-02-08 | 2024-09-17 | Emendobio Inc. | OMNI-103 CRISPR nuclease |
| AU2023276763A1 (en) | 2022-05-25 | 2024-12-12 | Metagenomi Therapeutics, Inc. | Supplementation of liver enzyme expression |
| AU2023308345A1 (en) * | 2022-07-15 | 2025-02-27 | Emendobio Inc. | Strategies for knock-ins at aplp2 safe harbor sites |
| WO2025117858A1 (en) * | 2023-11-28 | 2025-06-05 | Metagenomi, Inc. | Supplementation of liver enzyme expression |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512446B1 (en) * | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| US20220213456A1 (en) * | 2019-04-30 | 2022-07-07 | Emendobio Inc. | Novel omni crispr nucleases |
| BR112021021912A2 (pt) * | 2019-04-30 | 2022-01-18 | Emendobio Inc | Nova nuclease omni-50 crispr |
| US12435334B2 (en) * | 2019-11-06 | 2025-10-07 | Emendobio Inc. | Differential knockout of an allele of a heterozygous ELANE gene-II |
| EP4662307A1 (en) * | 2023-02-08 | 2025-12-17 | Emendobio Inc. | Engineered omni-50 nuclease variants |
-
2022
- 2022-08-12 IL IL310730A patent/IL310730A/en unknown
- 2022-08-12 US US18/682,982 patent/US20250283115A1/en active Pending
- 2022-08-12 KR KR1020247007872A patent/KR20240043792A/ko active Pending
- 2022-08-12 CA CA3228366A patent/CA3228366A1/en active Pending
- 2022-08-12 EP EP22856846.5A patent/EP4384609A4/en active Pending
- 2022-08-12 AU AU2022326575A patent/AU2022326575A1/en active Pending
- 2022-08-12 JP JP2024508545A patent/JP2024531217A/ja active Pending
- 2022-08-12 WO PCT/US2022/074930 patent/WO2023019263A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024531217A5 (https=) | ||
| EP3371310B1 (en) | Engineered nucleic-acid targeting nucleic acids | |
| EP3350327B1 (en) | Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids | |
| JP7649748B2 (ja) | Ｃｒｉｓｐｒ－ｃａｓエフェクターポリペプチド及びその使用方法 | |
| JP2023166400A5 (https=) | ||
| US6297029B1 (en) | Mammalian artificial chromosomes | |
| CN110799205A (zh) | 利用CRISPR-Cpf1的可诱导、可调和多重的人类基因调节 | |
| JP2019534695A (ja) | Ｒｎａ誘導型核酸修飾酵素及びその使用方法 | |
| AU2020358863A1 (en) | CRISPR systems with engineered dual guide nucleic acids | |
| CN119391700A (zh) | 利用人工构建rna编辑酶进行rna定点编辑及相关应用 | |
| US20190284581A1 (en) | Genome editing method | |
| WO2023240229A2 (en) | Compositions and methods for nucleic acid modifications | |
| JP2025518552A (ja) | 細胞を操作するための組成物及び方法 | |
| EP4370676A2 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| WO2025261230A1 (zh) | 一种工程化的细胞及其应用 | |
| KR20180128864A (ko) | 매칭된 5' 뉴클레오타이드를 포함하는 가이드 rna를 포함하는 유전자 교정용 조성물 및 이를 이용한 유전자 교정 방법 | |
| US20260022404A1 (en) | Compositions and methods for genome editing | |
| US20250197811A1 (en) | Compositions and methods for generating cells with reduced immunogenicity | |
| KR20240155953A (ko) | 진핵 유전자 편집을 위한 조성물, 시스템 및 방법 | |
| IL300563A (en) | Nuclease-mediated nucleic acid modification | |
| CN120082554B (zh) | 一种CRISPR/Cas12i介导的crRNA及其在敲除牛MSTN基因中的应用 | |
| WO2020055748A1 (en) | Modulators of cas9 polypeptides and methods of use thereof | |
| JP2025535776A (ja) | 遺伝子を標的化、編集又は修飾するための組成物及び方法 | |
| WO2025076084A1 (en) | Engineered nucleases and compositions and methods thereof | |
| TW202521691A (zh) | 經工程化之v型rna可程式核酸內切酶及其用途 |